Nature Awards — MDx Impact Grants (2026-2027)
Before you apply
About this call
The MDx Impact Grants are issued by Nature Awards in partnership with Seegene, and are oriented toward the democratization of PCR-based diagnostics for conditions where clinical need remains unmet. The 2026-2027 cycle concentrates this mandate on neurodegenerative disease, specifically Alzheimer's disease, and asks applicants to demonstrate how high-multiplex PCR platforms might enable the detection and characterization of molecular markers. The call is institutional and scientific in character rather than artistic; it is a targeted research funding instrument, and it should be read as such by any practitioner considering it. Successful applicants receive development grants of up to 600,000 USD to conduct clinical studies, together with access to Seegene's proprietary syndromic PCR technology. The program is open to eligible research groups worldwide, carries no application fee, and permits each group to submit a single application addressing the designated project. The scope is deliberately constrained: proposals are expected to articulate, with rigor, how the Seegene platform addresses the stated diagnostic problem, and to provide a credible route toward clinical utility rather than exploratory inquiry alone. The curatorial vision here is therefore one of translational precision. The award rewards methodological clarity, institutional readiness, and a defensible connection between platform capability and clinical need. Submission materials reflect this seriousness: applicants prepare a standalone application document, a pro forma service agreement to be shared with their institution's funding office, and evidence of in-principle approval from that office. Prospective applicants should weigh these administrative requirements before committing time to the proposal.
Eligibility
research groups; one application per research group
What to send
Required
Required
Required